Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, has recently made a collaboration with the University of California, San Francisco (“UCSF”) to develop 3D bioprinted tissues for skeletal disease research.
“Partnerships with world-class institutions can accelerate groundbreaking work in finding cures for critical unmet disease needs and the development of implantable therapeutic tissues,” said Keith Murphy, Chairman and CEO, Organovo. “This collaboration with UCSF, which combines their expertise with our own, is another important step in this direction. With the devoted support of the Methuselah foundation, leading researchers are able to leverage Organovo’s powerful technology platform to achieve significant breakthroughs.”
The partnership also includes the UCSF labs of Tamara Alliston, Chelsea Bahney, Jeff Lotz and Robert Nissenson. Under Methuselah’s University 3D Bioprinter Program, Methuselah is donating at least USD 500,000 in direct funding to be divided among several institutions for Organovo bioprinter research projects. “We at the Methuselah Foundation have been a long-time supporter of academic and industry research in 3D bioprinting, regenerative medicine, and tissue engineering,” said David Gobel, CEO, Methuselah Foundation. “Our University 3D Bioprinter Program puts Organovo’s breakthrough 3D bioprinting technology in the hands of the brightest scientists at tissue engineering centers of excellence.”